Prof Philippe Manivet (MD-PhD)
Philippe Manivet is a hospital Practitioner in Lariboisière hospital, Assistance Publique – Hôpitaux de Paris and Professor in Biochemistry and molecular Biology. He holds a PhD in Biochemistry and theoretical Chemistry from Ecole Polytechnique, Paris. He leads a research team at the INSERM unit 1141 NeuroDiderot, Paris, working on biomechanical and biochemical aspects of cell communications and cell/extracellular matrix interactions, in neurosciences and cancer. As a Director of the Biobank Lariboisière (biobank-lariboisiere.fr), P Manivet has built an ecosystem dedicated to the development of innovation in health. This ecosystem is gathering talented academic and private sector researchers, helping them in transforming their ideas into an innovation and toward entrepreneurship, by leading a market and medical needs-oriented R&D. The strategic position of the Biobank embedded into the hospital real life, close to the patients, as member of prestigious research networks, allow to de-risk any innovative project. SMEs find in this ecosystem a secure area for developing their own business. P Manivet is the founders of several start-up and SME.
Dr Anthony Treizebre (PhD)
Dr Anthony TREIZEBRE is an assistant professor at University of Lille 1 and researcher at the IEMN CNRS Institute begin 2007. After a first research topic dedicated to the signature of biological entities by high frequency spectroscopy (THz) in microfluidic environment. He has developed a track record expertise on micro-fabrication in clean room of instrumented microfluidic components with sensors and actuators. During the last four years, he has acquired a real expertise on the conception of endothelial barrier on chip to study the interactions cellular and the development of “Organ on Chip” on the scope of many pathologies like Cancer, Diabetes and cardiovascular diseases.
Prof. Szecheng J. Lo (PhD)
Received Ph. D. in cell biology at Wayne State University, Michigan, USA. Academic research interests in molecular biology of hepatitis (B, C and D) viruses and C. elegans model for nucleolus size control under bacteria infection. Current position: Visiting professor of Department of Biomedical Sciences, Chang Gung University. Member of Board, Science Monthly.
Previous positions and experience: Chairman of Department of Biomedical Sciences, Director of General Studies, Chang Gung University. Dean of Student Affair, Director of Graduate Institute of Microbiology and Immunology, National Yang Ming University. Editor-in-chief and a council member of Science Monthly. Co-authored with Yi-Ling Yang to publish popular science books of “Snake Venom Research in Taiwan” and “Hepatitis Combat” (Both in Chinese)
Dr Karine Hannebicque (MD)
Dr. Karine Hannebicque, is a surgeon in breast cancer and reconstructive surgery in Oscar Lambret Center in the Department of breast oncology since 2014. She is also Medical Coordinator of the Ambulatory Surgery Unit since 2018.
After her Internship in Obstetrics & Gynecology between 2004 and 2011, she had started her career as head of “Clinique des Universités” with 2 majors activities: obstetric and surgical activities before starting to work on carcinological and restorative breast surgery.
David Devos obtained his ‘Doctor of Neurology’ and ‘Doctor of Neuroscience’ degrees from the University of Lille, France. Between 2002 and 2010, he worked as a hospital physician in the Department of Neurology of the Centre Hospitalier Universitaire of Lille, where he is now Professor in Medical Pharmacology (Lille University, INSERM UMR_S1171).
His main research interest is the development of new disease-modifying strategies in neurodegenerative diseases, particularly Parkinson’s disease and amyotrophic lateral sclerosis, but also dementia and cerebellar ataxia.
His research is mainly based upon clinical trials but also includes preclinical, translational and clinical studies in neuropsychopharmacology. He was directly involved in 28 studies including 14 multicentric and 14 as the coordinator (8 in progress), including the European multicentric study, FAIRPARK-II, of Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease (http://fairpark2.eu). He received several prizes, notably the Prize of innovation “From Bench to bed” of Eurasanté in 2015 for the innovative therapeutic strategy of DIVE (Dopamine with intracerebroventricular administration) and the European pharmacology scientific award EACPT for the best scientific work of the two last years in 2013.
Karim Si-Tayeb has developed an expertise in human induced pluripotent stem cells (hiPSCs) differentiation and disease modelling. His experience on liver chronic disease acquired during his Ph.D. at the university of Bordeaux, France, and on liver development during his postdoctoral work at the Medical College of Wisconsin (Milwaukee, WI, USA) led him to focus his research on the study of liver metabolic disease. In 2012, he joined Bertrand Cariou’s team at the thorax institute in Nantes (http://www.umr1087.univ-nantes.fr/equipe-iv-dyslipidemies-et-lipotoxicite–1518230.kjsp) to study lipid disorders such as familial hypercholesterolemia and familial hypobetalipoproteinemia. He is currently participating to the RHU CHOPIN (https://rhuchopin.fr/), which aims at decreasing cardiovascular events in hypercholesterolemic patients through precision medicine.
Dr. Samuel Meignan is a senior researcher at the « Cell Plasticity and Cancer » Inserm U908 laboratory and the head of the Tumorigenesis and Resistance to Treatment Unit in Oscar Lambret Center (Lille, France).
He holds a Ph.D. in Cellular and Molecular Biology from Lille University for his works on the role of neurotrophins receptors in breast cancer cells phenotype, especially their sensitivity to apoptogenic agents. He joined Inserm U837 for a four years postdoctoral position in Antitumoral Pharmacology. In collaboration with Lille Faculty of Pharmacy and some pharmaceutical industries as Merck KGaA and Pierre Fabre Laboratories, he led evaluations of new antitumor compounds and innovative therapeutic strategies in different cancers as head and neck or pediatric brain tumors. He developed an expertise in drug testing in vitro and in vivo, but also in the understanding of mechanism leading to resistance to treatment. In 2013, Oscar Lambret cancer comprehensive center entrusted him the direction of its basic research unit refocused on deciphering and skirting of mechanisms involved in pediatric gliomas resistance to treatment. Currently, his main project aims to determine the role of H3.3K27M mutation in the low response to chemo and radiotherapy of Diffuse Intrinsic Pontine Gliomas.
He is a scientific expert for French Society of Fight Against Cancer and Leukemias of Children and Adolescents, and a referee for Journal of Applied Oral Science. He supervised a number of students including three Ph.D. and numerous master students. He also teaches master courses for “Biology & Health” at the Faculty of Medicine at Lille University.
Prof. Romeo Cecchelli graduated as a physiologist and holds a PhD in Physiology and a ‘Doctorat es sciences’ in Biochemistry from the University of Lille.
He soon became interested in the transport of drugs across the blood-brain barrier and in the early 90’s he set up, at the Pasteur Institute in Lille, an in vitro blood-brain barrier (BBB) model (consisting of a coculture of brain capillary endothelial cells and glial cells). This model has shown a high correlation between in vitro and in vivo permeability for a wide range of molecules. In 1997, he was appointed a full Professor in Cell Biology (Artois University, Lens, France) and was the first vice-president of Artois University in charge of the research from 2005 to 2015. He was involved in several European research programs: he was the coordinator of BBB follow-up (an ECVAM funded study, 2006-2007) and participated in FP6 ACUTOX (2006-2010), FP7 PREDICT IV and EUSTROKE (WP leader: In vitro models of the blood brain barrier, 2010-2013). He contributed to several research contracts with pharmaceutical companies (Servier, Sanofi Astrazeneca, etc.). In 2014, his lab developed a stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells (patent n°WO/2014/203087), showing a very nice correlation with human in vivo data.
Dr. Georg Haase, MD PhD, is a team leader at Institut de Neurosciences de la Timone in Marseille and co-coordinator of research on amyotrophic lateral sclerosis (ALS) at Marseille’s Center of Excellence in Neurodegeneration DHUNE.
Georg Haase has pioneered gene therapy approaches in ALS and investigated neurodegenerative pathways in cellular and and animal models of ALS and related motor neuron diseases. His lab has acquired unique expertise in isolating pure motor neurons by fluorescent-activated cell sorting (FACS) from human iPSc-derived cultures and embryonic mice and in analysing them by flow cytometry.